Advances in hypertension as reported at ACC 2025 include two new therapies that achieve significant blood pressure (BP) reduction, and a comparison of renal denervation methods for resistant BP.

Pulmonary arterial hypertension (PAH) is a rare and severe lung disease with a life-threatening prognosis. After several positive trials, a recent study has confirmed the efficacy of a biotherapy, ...

But for some women, the postpartum journey can include unexpected health challenges—one of which is postpartum hypertension. While it may sound alarming, understanding this condition can go a ...

1 Department of Neurology and Neurological Surgery (Neurology), Washington University School of Medicine, St Louis, MO, USA 2 American Parkinson Disease Association Advanced Center for Parkinson ...

None of them focused specifically on adherence to pharmacological therapy for hypertension in Portugal. Considering the high prevalence of non-adherence and its location-specific aspects, the priority ...

CHICAGO — The addition of lorundrostat, an investigational drug, to the treatment regimen of people with well-treated but uncontrolled and resistant hypertension could be beneficial, new data show.

The Advance-HTN trial showed that lorundrostat effectively lowered 24-hour SBP at 12 weeks among patients with uncontrolled and treatment-resistant hypertension vs. placebo. Participants at 103 U.S.

Pulmonary arterial hypertension (PAH) is a type of pulmonary hypertension that causes high blood pressure in the small arteries of the lungs. It is a serious condition that can impair blood flow, ...

A group of 29 international experts says that simultaneous screening for hypertension and heart arrhythmia could prevent thousands of strokes. A recent expert review highlights the strong link ...